Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 1;48(5):e71-e73.
doi: 10.2337/dc25-0272.

Oral Glucagon-Like Peptide 1 Analog as an Adjuvant Therapy in Generalized Lipodystrophy

Yael Lebenthal  1   2 , Sharon Halperin  3 , Hagar Interator  1   4 , Avivit Brener  1   2 , Rebecca J Brown  5
Affiliations

Oral Glucagon-Like Peptide 1 Analog as an Adjuvant Therapy in Generalized Lipodystrophy

Yael Lebenthal et al. Diabetes Care. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Duality of Interest. Y.L. is the head of an institute that receives research grants from Medison Pharma, Novo Nordisk, Pfizer, and Sanofi. Y.L. has also received speaker fees and travel grants and served on advisory boards for Medison Pharma, Novo Nordisk, Pfizer, and Sanofi. R.J.B. receives research support from Chiesi, Marea Therapeutics, Pfizer, and Regeneron. No other potential conflicts of interest relevant to this article were reported.

References

    1. Brown RJ, Araujo-Vilar D, Cheung PT, et al. . The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline. J Clin Endocrinol Metab 2016;101:4500–4511 - PMC - PubMed
    1. Brown RJ, Oral EA, Cochran E, et al. . Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy. Endocrine 2018;60:479–489 - PMC - PubMed
    1. Lamothe S, Belalem I, Vantyghem MC, et al. . Safety and effectiveness in an uncontrolled setting of glucagon-like-peptide-1 receptor agonists in patients with familial partial lipodystrophy: real-life experience from a national reference network. Diabetes Obes Metab 2025; 27:1815–1825 - PMC - PubMed
    1. Oliveira J, Lau E, Carvalho D, Freitas P.. Glucagon-like peptide-1 analogues - an efficient therapeutic option for the severe insulin resistance of lipodystrophic syndromes: two case reports. J Med Case Rep 2017;11:12. - PMC - PubMed
    1. Foss-Freitas MC, Imam S, Neidert A, Gomes AD, Broome DT, Oral EA.. Efficacy and safety of glucagon-like peptide 1 agonists in a retrospective study of patients with familial partial lipodystrophy. Diabetes Care 2024;47:653–659 - PMC - PubMed

LinkOut - more resources